Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to fighting cancer using RNA-based therapies, in collaboration with teams from Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancer title, Clinical applications of RNA-based short non-coding RNA Therapies in the era of precision medicine. The article was published on March 21, 2022.
The article describes the development, challenges and clinical successes of short RNA drugs and details several examples of how these RNA drugs are designed, chemically modified and delivered for the treatment of cancer, cardiovascular diseases and rare genetic diseases. Additionally, the article highlights key similarities and differences between the various short non-coding RNA platforms and discusses considerations for maximizing the treatment efficacy of RNA-based therapies. TransCode co-founder and scientific advisor Dr. Anna Moore contributed to the article.
“The field of RNA-based therapies has matured to the point of translation into the clinic and is poised to transform the way we treat disease over the next decade,” commented Dr. Zdravka Medarova, Co-Founder and Chief Technology Officer of TransCode. “This report provides an overview of the field of RNA therapeutics and describes the future of short non-coding RNAs as a therapeutic platform for a wide range of disorders, including cancer.”
TransCode CEO Michael Dudley added, “We believe that RNA-based medicines will play an increasingly important role in the personalized treatment of cancer and other diseases. Our first-in-man clinical trial, which we plan to launch later this year with our lead therapeutic candidate, targets an RNA molecule that has been shown to drive metastatic disease. Since our proprietary delivery system was designed to deliver therapeutic RNAs inside tumor cells, it has the potential to overcome the challenges of delivering RNA to a range of genetic targets. We believe this would represent a major step forward in unlocking therapeutic access to genetic targets implicated in a range of cancers.
This article in Cancer further supports the potential of our drug candidate platform and reaffirms our belief that cancer can be defeated through the intelligent design and efficient delivery of RNA-based therapies.